Itron, Inc. Message Board
-
yp_peter:
What are you talking about? If you own these shares, you DO NOT want "many more shares" out there. The fewer shares the better.Sentiment: Buy
-
Yes. For only 3,000,000 shares I would have gladly paid $4.30+/share. I am quite concerned that the Frenchmen managing this company did not ask me to buy those shares!
Sentiment: Buy
-
I looked at all etrade news releases for EDAP since May 1st, but there is nothing there from Thomson-Reuters. This guy has sold EDAP short, is losing a bundle and trying to recover.
Sentiment: Buy
-
...............makes it look like the September review of EDAP by the American review team will be very positive, most likely opening the USA as a key country for future utilization of this very positive technology.
Sentiment: Strong Buy
-
Middleby is a food service firm. Could you think of a more boring area in which to operate? And there is really almost zero analyst coverage. Stick with it. I'm up 350% even though no one ever heard of the firm.
Sentiment: Strong Buy
-
Seeking Alpha just listed SBS as the second best Brazilian stock. Should we really be seeing such a poor performance?
Sentiment: Buy
-
Take a good look. 38% of all GMCR shares were shorted yesterday AM. They have to get out, but no one can tell them how they can do it!
Sentiment: Strong Buy
-
"Insider selling" is not the correct term. In the past 6 months, insiders have sold 94.5% of all of their shares. This is not "insider selling." It is "total capitulation."
Sentiment: Sell
-
Take a good look at EZCorp's share price over the past couple of years. Down, down, down. Yet everything looks quite rosy for its next couple of years. I believe that a price of $27/share is not unrealistic by January 1st.
Sentiment: Buy
-
Can someone explain the effect of the new regulation announced this morning? Thank you.
-
The report yesterday by ISRG could not have been more positive. On a day when its stock should be up by 10% or so, we are down. Greenberg thinks that he is a great big winner. But this is not correct. In the end, ISRG will win big time. I am certain that, within six months, its price will exceed $550/share. You can quote me on that one.
Sentiment: Strong Buy
-
The FDA has already sent at least two indications to EDAP that they are currently in the process of considering its submission for approval, possibly by September. It is really interesting how investors in this country have taken very little consideration of this matter, at least in 2013.
Sentiment: Buy
-
It looks like all of the drop today is due to a few holders of lots of shares (i.e. hedge funds, mutual funds, wealthy guys, etc.) I agree that the up market in thisstock should resume shortly.
Sentiment: Buy
-
I bought ISRG about 10 years ago at $15/share. It is now about $450/share. Both companies attack prostate cancer. For its first 5 years, ISRG's price went nowhere. That is where EDAP is right now. But, I believe that its future is very bright. I say "buy and hold."
Sentiment: Strong Buy
-
You can read that article as the most recent posted. It is quite interesting that JST is the number one Ben Graham stock out of all the stocks out there. Perhaps it's relatively poor showing during the past two years relates to the fact that Ben has few followers in today's stock market.
Sentiment: Strong Buy
- Reply to
Massachutes will be the 1st state to limit robotic surgery, next obamacare
by thebrownrooster52 •Mar 20, 2013 10:49 AMNo. Massachusetts said nothing of the kind. Some people, such as yourself, have sold this great stock short.
-
EDAP's ultrasound cancer therapy reminds me of ISRG 15 years ago. ISRG has moved from $15/share to over $500/share during this time, largely on its DaVinci therapy for primarily prostate cancer. Of course, ISRG has been expanded to many other disease treatments.
EDAP's ultrasound therapy has been used on over 40,000 patients in just about every country in the world except for the USA. I see no possible way by which the FDA will block this role on its evaluation in just a couple of months. -
.....14 years ago. And, during the many crashes in its price, I never sold a share. The $1,000/share will, I believe, materialize by 2016.
-
.............when ISRG fell to less than $100/share. I purchased ISRG at $15/share about 14 years ago and have never sold a share. Thank goodness!
Sentiment: Strong Buy
-
Yes. It is certainly interesting how HIFU cancer therapy has been approved for use in just about every country in the world except for the USA. I guess that the concept that the phama companies have successfully blocked its use is probably correct. But, my only question is: For how much longer?